Company Data

Alpha Cognition Inc

Current Price
$0.6 10.6%
Market Cap
Price Target
Refer to Report
52wk Range
$0.1638 - $0.7398
Advanced Market Data


Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The Company¿s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company¿s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein.

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy